AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6408940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6408940 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation (blood tests)
Number of subjects: 51
Study 30826693 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion focused orientation
Number of subjects: 2064
Study 30826693 — intervention group
Group type: EXPERIMENTAL
Intervention: Present hedonistic perspective
Number of subjects: 2064
Study 30826693 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal locus of control
Number of subjects: 2064
Study 30826693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation seeking
Number of subjects: 2064
Study 30419038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for social activation (CBTsa)
Number of subjects: 99
Study 30419038 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 99
Study 26504778 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistep dissemination strategy
Number of subjects: 1627
Study 26504778 — intervention group
Group type: COMPARATOR
Intervention: Brochure only dissemination strategy
Number of subjects: 1627
Study 26504778 — intervention group
Group type: EXPERIMENTAL
Intervention: Monothematic dissemination strategy
Number of subjects: 1627
Study 26504778 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive dissemination strategy
Number of subjects: 1627
Study 26504778 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite tobacco prevention measures
Number of subjects: 1627
Study 23867242 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (1 hour, twice per week for 4 weeks)
Number of subjects: 30
Study 23867242 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study 22944289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (3-5Fr, 5-7cm long), removed endoscopically 1-2 weeks post-ERCP
Number of subjects: 191
Study 22944289 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic duct stenting (no-stent group)
Number of subjects: 191
Study 22944289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting
Number of subjects: 191
Study 22944289 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic duct stenting
Number of subjects: 191
Study 19302903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral SAMe (1000 mg)
Number of subjects: 20
Study 19302903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose IV SAMe (1000 mg)
Number of subjects: 20
Study 19302903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose oral SAMe (1000 mg)
Number of subjects: 20
Study 19302903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose IV SAMe (1000 mg)
Number of subjects: 20
Study 17825690 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 25/50 microg/actuation (group 1), 25/125 microg/actuation (group 2), or 25/250 microg/actuation (group 3), administered as 2 inhalations BID for 52 weeks.
Number of subjects: 325
Study 15131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (training in optic disc assessment, explicit referral criteria, and ophthalmologist feedback)
Number of subjects: 397
Study 15131679 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 397
Study 15131679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 397
Study 11725825 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg cisapride orally three times daily for 7 days
Number of subjects: 30
Study 11725825 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 age-matched controls)
Number of subjects: 30
Study 11725825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 30
Study 9922587 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 MU over 1 hour)
Number of subjects: 29
Study 9922587 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA (100 mg in 1.5 hours)
Number of subjects: 29
Study 9922587 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-t-PA (30-40 mg in 15 s)
Number of subjects: 29
Study 9922587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thrombolysis)
Number of subjects: 29
Study 9121623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.08 mg nicotine yield
Number of subjects: 32
Study 9121623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.17 mg nicotine yield
Number of subjects: 32
Study 9121623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.37 mg nicotine yield
Number of subjects: 32
Study 9121623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.48 mg nicotine yield
Number of subjects: 32
Study 9121623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.74 mg nicotine yield
Number of subjects: 32
Study 2156649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days after pretreatment with 1,25-dihydroxyvitamin D
Number of subjects: 36
Study 2156649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days with placebo pretreatment
Number of subjects: 36
Study 2156649 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (500 mg) administered daily for 7 days to normal control subjects
Number of subjects: 36
Study 2156649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg) administered daily for 7 days after pretreatment with placebo
Number of subjects: 36
Study 113129 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 384
Study 113129 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 384
Study 113129 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with all grafts patent
Number of subjects: 384
Study 113129 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with all grafts closed
Number of subjects: 384
Study 31706315 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning CPR education program
Number of subjects: 120
Study 31706315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 26237073 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group rehabilitation program
Number of subjects: 41
Study 26237073 — intervention group
Group type: COMPARATOR
Intervention: General health orientation about KOA (Control Group)
Number of subjects: 41
Study 21755368 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual motion cue (Experiment 1)
Number of subjects: 0
Study 21755368 — intervention group
Group type: EXPERIMENTAL
Intervention: Static cue (Experiment 2)
Number of subjects: 0
Study 21624304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human brain natriuretic peptide (rhBNP)
Number of subjects: 2160
Study 19139364 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 1403
Study 19139364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1403
Study 16753722 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured learning
Number of subjects: 138
Study 16753722 — intervention group
Group type: COMPARATOR
Intervention: Student-directed learning
Number of subjects: 138
Study 15499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann perimeter
Number of subjects: 100
Study 15499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Colvard pupillometer
Number of subjects: 100
Study 15499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (scotopic)
Number of subjects: 100
Study 15499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (mesopic low)
Number of subjects: 100
Study 15499519 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyon Video pupillometer (mesopic high)
Number of subjects: 100
Study 11258044 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxin tablets 5 mg (test formulation)
Number of subjects: 23
Study 9167863 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session treatment for spider phobia
Number of subjects: 0
Study 9167863 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated spider phobics)
Number of subjects: 0
Study 1396766 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA using the purified 120 kDa protein
Number of subjects: 127
Study 1396766 — intervention group
Group type: COMPARATOR
Intervention: EIA using whole cell sonicate of a single Helicobacter pylori strain
Number of subjects: 127
Study 1396766 — intervention group
Group type: COMPARATOR
Intervention: Western immunoblot
Number of subjects: 127
Study 2990350 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNU and radiation therapy
Number of subjects: 71
Study 2990350 — intervention group
Group type: COMPARATOR
Intervention: MCNU alone
Number of subjects: 71
Study 30704266 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol/budesonide inhalation (4·5 µg/80 µg, twice daily) plus intranasal budesonide 64 µg twice daily (group A)
Number of subjects: 121
Study 30704266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cellulose powder (ICP) 250 µg thrice daily (group B)
Number of subjects: 121
Study 30704266 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo 250 µg thrice daily (group C)
Number of subjects: 121
Study 28109045 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 149
Study 28109045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 26651419 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter storage red blood cell transfusions
Number of subjects: 31497
Study 26651419 — intervention group
Group type: COMPARATOR
Intervention: Longer storage red blood cell transfusions
Number of subjects: 31497
Study 25046279 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (250/50 μg twice daily) combined with TIO (18 μg once daily)
Number of subjects: 56
Study 25046279 — intervention group
Group type: COMPARATOR
Intervention: TIO alone (18 μg once daily)
Number of subjects: 56
Study 22799589 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir 400 mg single dose
Number of subjects: 24
Study 22799589 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg single dose
Number of subjects: 24
Study 22799589 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg single dose (Day 1 and Day 4)
Number of subjects: 24
Study 22799589 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 20600990 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.7 mmol/l) for 1 h
Number of subjects: 17
Study 20600990 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting glucose (5 mmol/l) for 1 h
Number of subjects: 17
Study 17681023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 0
Study 17681023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16129968 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 16129968 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 12403238 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (300 microg/day for 9-60 months)
Number of subjects: 145
Study 12403238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no inhaled corticosteroids)
Number of subjects: 145
Study 10464846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bambuterol (20 mg nocte)
Number of subjects: 117
Study 10464846 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms b.i.d.)
Number of subjects: 117
Study 10464846 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bambuterol and salmeterol
Number of subjects: 117
Study 8545518 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 8545518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) 1 h before induction (group 2)
Number of subjects: 60
Study 2301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) on the evening before surgery and 1 h before induction (group 3)
Number of subjects: 60
Study 2301751 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.3 mg/kg) 1 h before induction (group 1)
Number of subjects: 60
Study 2301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) (group 2)
Number of subjects: 60
Study 2301751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) (group 3)
Number of subjects: 60
Study 2301751 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 6989685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamethacin (100 mg t.i.d.)
Number of subjects: 339
Study 6989685 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 339
Study 31667606 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB)
Number of subjects: 3000
Study 31667606 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 3000
Study 28946113 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles for one week
Number of subjects: 19
Study 28946113 — intervention group
Group type: COMPARATOR
Intervention: Conventional insoles after one week
Number of subjects: 19
Study 26284338 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane treatment (EC/T arm)
Number of subjects: 1097
Study 26284338 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF treatment (CEF arm)
Number of subjects: 1097
Study 26284338 — intervention group
Group type: EXPERIMENTAL
Intervention: TLE3 positive tumors (TLE3+)
Number of subjects: 1097
Study 26284338 — intervention group
Group type: EXPERIMENTAL
Intervention: TLE3 expression
Number of subjects: 1097
Study 23694947 — intervention group
Group type: EXPERIMENTAL
Intervention: MCIc (converted to Alzheimer disease)
Number of subjects: 110
Study 23694947 — intervention group
Group type: COMPARATOR
Intervention: MCInc (stable MCI)
Number of subjects: 110
Study 21866329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal programme incorporating pool‐based exercise using deep water running (DWR) three times a week for an 8‐week period
Number of subjects: 44
Study 21866329 — intervention group
Group type: COMPARATOR
Intervention: Leaflet containing advice and continued normal activities
Number of subjects: 44
Study 19040689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education
Number of subjects: 148
Study 19040689 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized education with peak flow monitoring
Number of subjects: 148
Study 19040689 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 17362223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Instrument (ensemble format)
Number of subjects: 0
Study 17362223 — intervention group
Group type: COMPARATOR
Intervention: Traditional Instrument (interleafed format)
Number of subjects: 0
Study 15142022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular training
Number of subjects: 25
Study 15142022 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 25
Study 15142022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 11578885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol (Group P)
Number of subjects: 106
Study 11578885 — intervention group
Group type: COMPARATOR
Intervention: 0.3 microg/kg remifentanil (Group R)
Number of subjects: 106
Study 9661868 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum relaxin concentration measured by ELISA
Number of subjects: 2185
Study 9661868 — intervention group
Group type: COMPARATOR
Intervention: Hip instability assessment via anterior-dynamic ultrasound
Number of subjects: 2185
Study 7841695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) of 0.5 s and expiratory time (TE) of 0.5 s at 60 breaths/min
Number of subjects: 25
Study 7841695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) > or = 0.5 s
Number of subjects: 25
Study 7841695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory time (TI) of 1.0, 0.67, and 0.5 s with expiratory times (TE) of 1.0, 1.33, and 1.5 s at 30 breaths/min
Number of subjects: 25
Study 2437967 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (25 mg vaginal suppositories twice daily)
Number of subjects: 56
Study 2437967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol)
Number of subjects: 56
Study 2437967 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone treatment
Number of subjects: 56
Study 2437967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30737047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 151
Study 30737047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction plus fish oil supplementation (CRF)
Number of subjects: 151
Study 30737047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restricted meal replacement (CRMR)
Number of subjects: 151
Study 30737047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restricted meal replacement with fish oil supplementation (CRMRF)
Number of subjects: 151
Study 30737047 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp 1-1 phenotype
Number of subjects: 151
Study 30864188 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1,500 mg daily for 10 weeks)
Number of subjects: 44
Study 28697810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered intimate partner violence screening, supportive care and referral intervention
Number of subjects: 0
Study 25122587 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program (MLWP)
Number of subjects: 71
Study 25122587 — intervention group
Group type: COMPARATOR
Intervention: Body-Weight-Supported Treadmill Training (BWSTT)
Number of subjects: 71
Study 25122587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MLWP and BWSTT)
Number of subjects: 71
Study 23138389 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurolysis of the stellate ganglion
Number of subjects: 67
Study 23138389 — intervention group
Group type: COMPARATOR
Intervention: Stellate ganglion blockade
Number of subjects: 67
Study 21959800 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A (400mg Norfloxacin)
Number of subjects: 18
Study 21959800 — intervention group
Group type: COMPARATOR
Intervention: Drug B (400mg Norfloxacin)
Number of subjects: 18
Study 18804915 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Pain Rehabilitation Program (CPRP) with opioid withdrawal, 3-week duration
Number of subjects: 373
Study 18804915 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid group
Number of subjects: 373
Study 15915407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nesiritide
Number of subjects: 237
Study 15915407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 12777951 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg/daily)
Number of subjects: 20
Study 12777951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10490862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 0
Study 10490862 — intervention group
Group type: COMPARATOR
Intervention: Casual Blood Pressure (CBP) measurements
Number of subjects: 0
Study 8558222 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive screening including CT scans and bilateral bone marrow biopsies
Number of subjects: 44
Study 8558222 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant therapy with high-dose chemotherapy and autologous bone marrow support (ABMT)
Number of subjects: 44
Study 2066763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (PE)
Number of subjects: 140
Study 2066763 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 140
Study 6134604 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg intravenously
Number of subjects: 12
Study 6134604 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg intravenously
Number of subjects: 12
Study 6134604 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 10 mg intravenously
Number of subjects: 12
Study 6134604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31116675 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1/L1 antibody
Number of subjects: 1747
Study 28790131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) game
Number of subjects: 456
Study 28790131 — intervention group
Group type: COMPARATOR
Intervention: Civics game
Number of subjects: 456
Study 26116581 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (omega-3 PUFAs)
Number of subjects: 0
Study 26116581 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 26116581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26116581 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs and Aspirin
Number of subjects: 0
Study 25483663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (monthly doses); mean levels in PICU-admitted subjects were 47.2 μg/mL, while non-PICU subjects had 98.7 μg/mL (P < 0.0001).
Number of subjects: 48
Study 25483663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab level at RSVH; levels ≥ 92 μg/mL showed no PICU admissions.
Number of subjects: 48